TRex Bio IPO raises $116.7 million, prices at bottom of range
TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.
How this was made
The 30-second read
Why it matters
The IPO provides capital for advancing its pipeline, but the modest cash balance and net loss raise execution risk.
Market read
First‑day pricing at the low end of the range creates a clear trading catalyst for the new listing.
What to watch
Potential dilution from future secondary offerings and the company's cash burn rate could limit upside.
Background
TRex Bio is a clinical‑stage biotech focused on autoimmune and inflammatory diseases, with lead candidates in Phase 1b trials.
Market effects
Adds another biotech IPO to a strong 2026 US biotech fundraising wave, may boost sector sentiment.
Supports Nasdaq biotech listings momentum in the US West Coast region.
Highlights continued investor appetite for clinical‑stage biotech despite broader market conditions.
Counterpoint
If demand is weak, the floor price could lead to immediate post‑IPO sell‑off as investors lock in gains.
Key entities
- companyTRex Bio Inc.
Clinical‑stage biotech launching on Nasdaq under ticker TRXB.
- investorEli Lilly and Co.
Backer of TRex Bio, potential shareholder post‑IPO.
